Clinical Trial Matcher

NCT05610865

Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers

Recruiting · Phase 1 · University of the Punjab · registry updated 2024-12-31

Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.

The aim of this study is to evaluate the therapeutic efficacy of uncultured adipose derived stromal vascular fraction (SVF) and cultured adipose derived stem cells (ASCs) both supplemented with platelet rich plasma (PRP) to treat chronic diabetic foot ulcers. It will increase the pragmatic potential of both types of cells as PRP is rich in survival and chemotactic factors. Moreover, the autologous nature of the proposed study will ensure safety of its use in diabetic patients and will unveil the more effective therapeutic option for treatment of foot ulcer wounds.

Inclusion

  • Type 1 or Type 2 Diabetes Mellitus
  • Age 20-60 years (Male/Female)
  • Body mass index 20-30 kg/m2
  • Suitable for liposuction
  • Condition or Disease: Diabetic Neuropathy
  • Wound Type: Chronic foot ulcer

Exclusion

  • Uncontrolled hyperglycemia (HbAlc \> 9%)
  • Presence of severe clinical sign of infection
  • Inability to tolerate off-loading, and poor prognosis diseases including malignant tumors.
  • Serious chronic disease i.e hepatic, heart, renal, pulmonary diseases
  • Patients with critical limb ischemia and osteomylitis
  • Withdrawal of informed consent

Open NCT05610865 on ClinicalTrials.govAll conditions

Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers | Clinical Trial Matcher